Heron Therapeutics (HRTX) Financials

$2.01 -0.05 (-2.43%)

As of 04:00 PM Eastern

Annual Income Statements for Heron Therapeutics

This table shows Heron Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-182	-111	-14
Consolidated Net Income / (Loss)	-182	-111	-14
Net Income / (Loss) Continuing Operations	-182	-111	-14
Total Pre-Tax Income	-182	-111	-14
Total Operating Income	-175	-111	-12
Total Gross Profit	53	62	106
Total Revenue	108	127	144
Operating Revenue	108	127	144
Total Cost of Revenue	55	65	39
Operating Cost of Revenue	55	65	39
Total Operating Expenses	227	173	117
Selling, General & Admin Expense	62	66	53
Marketing Expense	83	68	47
Research & Development Expense	83	39	17
Total Other Income / (Expense), net	-7.37	0.06	-2.05
Interest Expense	2.47	3.87	6.03
Interest & Investment Income	1.64	3.36	3.55
Other Income / (Expense), net	-6.53	0.56	0.43
Basic Earnings per Share	($1.67)	($0.80)	($0.09)
Weighted Average Basic Shares Outstanding	108.88M	138.14M	152.45M
Diluted Earnings per Share	($1.67)	($0.80)	($0.09)
Weighted Average Diluted Shares Outstanding	108.88M	138.14M	152.45M
Weighted Average Basic & Diluted Shares Outstanding	119.26M	150.33M	152.33M

This table shows Heron Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-42	-20	-33	-42	-25	-11	-3.16	-9.24	-4.85	3.66
Consolidated Net Income / (Loss)	-42	-20	-33	-42	-25	-11	-3.16	-9.24	-4.85	3.66
Net Income / (Loss) Continuing Operations	-42	-20	-33	-42	-25	-11	-3.16	-9.24	-4.85	3.66
Total Pre-Tax Income	-42	-20	-33	-42	-25	-10	-4.80	-9.24	-4.46	4.91
Total Operating Income	-42	-20	-33	-42	-25	-10	-4.80	-6.45	-4.46	4.17
Total Gross Profit	12	17	13	12	13	24	26	26	23	31
Total Revenue	27	30	30	32	31	34	35	36	33	41
Operating Revenue	27	30	30	32	31	34	35	36	33	41
Total Cost of Revenue	15	13	17	20	18	9.89	8.44	11	9.46	10
Operating Cost of Revenue	15	13	17	20	18	9.89	8.44	11	9.46	10
Total Operating Expenses	54	38	46	54	38	35	31	32	28	26
Selling, General & Admin Expense	9.80	34	16	20	16	14	15	14	12	12
Marketing Expense	18	18	21	21	13	12	11	14	11	11
Research & Development Expense	26	-14	8.84	13	9.29	7.80	4.61	4.43	4.47	3.18
Total Other Income / (Expense), net	0.00	0.46	0.00	0.00	0.00	0.06	0.00	-2.79	0.00	0.74
Basic Earnings per Share	($0.38)	($0.11)	($0.27)	($0.35)	($0.17)	($0.01)	($0.02)	($0.06)	($0.03)	$0.02
Weighted Average Basic Shares Outstanding	111.74M	108.88M	119.25M	119.72M	144.99M	138.14M	151.20M	152.31M	152.83M	152.45M
Diluted Earnings per Share	($0.38)	($0.11)	($0.27)	($0.35)	($0.17)	($0.01)	($0.02)	($0.06)	($0.03)	$0.02
Weighted Average Diluted Shares Outstanding	111.74M	108.88M	119.25M	119.72M	144.99M	138.14M	151.20M	152.31M	152.83M	152.45M
Weighted Average Basic & Diluted Shares Outstanding	118.89M	119.26M	119.71M	140.76M	150.07M	150.33M	150.65M	151.67M	152.09M	152.33M

This table details how cash moves in and out of Heron Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-75	13	-2.88
Net Cash From Operating Activities	-147	-59	-23
Net Cash From Continuing Operating Activities	-147	-59	-23
Net Income / (Loss) Continuing Operations	-182	-111	-14
Consolidated Net Income / (Loss)	-182	-111	-14
Depreciation Expense	2.89	2.90	2.49
Amortization Expense	-0.53	-1.40	-1.18
Non-Cash Adjustments To Reconcile Net Income	43	33	17
Changes in Operating Assets and Liabilities, net	-11	17	-28
Net Cash From Investing Activities	-3.32	18	19
Net Cash From Continuing Investing Activities	-3.32	18	19
Purchase of Property, Plant & Equipment	-1.83	-1.55	-1.71
Purchase of Investments	-146	-88	-103
Sale of Property, Plant & Equipment	0.23	0.01	0.03
Sale and/or Maturity of Investments	144	107	123
Net Cash From Financing Activities	75	54	0.94
Net Cash From Continuing Financing Activities	75	54	0.94
Repayment of Debt	0.00	24	0.00
Issuance of Common Equity	77	31	0.64
Other Financing Activities, net	-1.53	-0.90	0.30
Cash Interest Paid	2.25	3.06	4.86

This table details how cash moves in and out of Heron Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	1.83	-35	12	-14	21	-6.18	-8.23	-2.06	7.36	0.06
Net Cash From Operating Activities	-37	-38	-25	-27	-9.18	2.46	-9.52	-4.60	3.37	-12
Net Cash From Continuing Operating Activities	-37	-38	-25	-27	-9.18	2.46	-9.52	-4.60	3.37	-12
Net Income / (Loss) Continuing Operations	-42	-20	-33	-42	-25	-11	-3.16	-9.24	-4.85	3.66
Consolidated Net Income / (Loss)	-42	-20	-33	-42	-25	-11	-3.16	-9.24	-4.85	3.66
Depreciation Expense	0.71	0.79	0.72	0.74	0.73	0.72	0.69	0.64	0.58	0.58
Amortization Expense	-0.20	-0.52	-0.42	-0.31	-0.27	-0.40	-0.50	-0.43	-0.17	-0.09
Non-Cash Adjustments To Reconcile Net Income	11	11	8.10	14	6.84	4.47	3.55	7.84	3.55	2.41
Changes in Operating Assets and Liabilities, net	-6.88	-29	-0.53	0.39	8.53	8.40	-10	-3.42	4.25	-18
Net Cash From Investing Activities	-36	2.02	37	13	-23	-8.84	1.28	2.05	3.97	11
Net Cash From Continuing Investing Activities	-36	2.02	37	13	-23	-8.84	1.28	2.05	3.97	11
Purchase of Property, Plant & Equipment	-0.05	-0.41	-0.22	-0.28	-0.79	-0.25	0.00	-0.64	-0.43	-0.64
Purchase of Investments	-68	-19	-14	-14	-36	-23	-38	-27	-26	-12
Sale of Property, Plant & Equipment	0.17	0.00	0.00	-	-	0.01	0.00	-	-	0.03
Sale and/or Maturity of Investments	32	21	51	28	14	15	39	30	30	24
Net Cash From Financing Activities	75	0.44	-0.21	0.32	54	0.20	0.01	0.49	0.01	0.42
Net Cash From Continuing Financing Activities	75	0.44	-0.21	0.32	54	0.20	0.01	0.49	0.01	0.42
Issuance of Common Equity	75	0.65	0.00	0.70	30	0.20	0.00	0.18	-	0.46
Other Financing Activities, net	-0.22	-0.22	-0.21	-0.39	-0.31	-0.00	0.01	0.32	0.01	-0.04
Cash Interest Paid	-	1.13	0.00	1.13	0.16	1.77	0.65	1.78	0.66	1.77

This table presents Heron Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	251	223	233
Total Current Assets	205	189	209
Cash & Equivalents	15	29	26
Short-Term Investments	69	52	33
Accounts Receivable	52	60	79
Inventories, net	55	42	53
Prepaid Expenses	14	6.12	18
Plant, Property, & Equipment, net	22	20	15
Total Noncurrent Assets	23	14	9.27
Other Noncurrent Operating Assets	23	14	9.27
Total Liabilities & Shareholders' Equity	251	223	233
Total Liabilities	237	256	267
Total Current Liabilities	82	80	91
Accounts Payable	3.23	3.24	12
Accrued Expenses	63	64	67
Current Employee Benefit Liabilities	13	9.22	9.55
Other Current Liabilities	2.69	3.08	3.04
Total Noncurrent Liabilities	155	177	175
Long-Term Debt	149	174	150
Other Noncurrent Operating Liabilities	5.74	3.04	26
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	14	-34	-34
Total Preferred & Common Equity	14	-34	-34
Preferred Stock	0.00	0.00	0.00
Total Common Equity	14	-34	-34
Common Stock	1,809	1,872	1,886
Retained Earnings	-1,795	-1,906	-1,920
Accumulated Other Comprehensive Income / (Loss)	-0.02	0.01	0.01

This table presents Heron Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	272	221	201	229	218	218	221
Total Current Assets	224	178	165	194	186	191	195
Cash & Equivalents	50	27	13	35	20	18	26
Short-Term Investments	71	33	20	43	51	49	45
Accounts Receivable	42	51	77	64	65	74	67
Inventories, net	52	52	45	42	42	43	46
Prepaid Expenses	7.63	15	11	11	6.58	7.25	11
Plant, Property, & Equipment, net	23	22	21	21	19	16	15
Total Noncurrent Assets	26	21	15	14	13	11	10
Other Noncurrent Operating Assets	26	21	15	14	13	11	10
Total Liabilities & Shareholders' Equity	272	221	201	229	218	218	221
Total Liabilities	250	232	241	257	252	256	261
Total Current Liabilities	94	78	87	80	75	80	86
Accounts Payable	6.55	4.07	1.96	1.86	0.84	10	10
Accrued Expenses	70	62	72	65	64	60	64
Current Employee Benefit Liabilities	15	9.51	9.86	10	7.65	7.09	8.53
Other Current Liabilities	2.62	2.76	2.58	3.00	3.14	3.19	3.25
Total Noncurrent Liabilities	156	154	154	177	176	176	175
Long-Term Debt	149	149	149	173	174	174	174
Other Noncurrent Operating Liabilities	0.24	5.07	4.40	3.78	2.29	1.53	0.76
Total Equity & Noncontrolling Interests	22	-11	-39	-28	-34	-38	-40
Total Preferred & Common Equity	22	-11	-39	-28	-34	-38	-40
Total Common Equity	22	-11	-39	-28	-34	-38	-40
Common Stock	1,798	1,817	1,831	1,868	1,875	1,880	1,883
Retained Earnings	-1,776	-1,828	-1,870	-1,895	-1,909	-1,918	-1,923
Accumulated Other Comprehensive Income / (Loss)	-0.06	0.01	-0.01	-0.00	-0.01	-0.01	0.04

This table displays calculated financial ratios and metrics derived from Heron Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	24.70%	17.99%	13.57%
EBITDA Growth	16.61%	39.30%	90.98%
EBIT Growth	17.15%	39.26%	89.92%
NOPAT Growth	19.82%	36.67%	89.58%
Net Income Growth	17.52%	39.26%	87.72%
EPS Growth	25.45%	52.10%	88.75%
Operating Cash Flow Growth	27.76%	59.98%	61.68%
Free Cash Flow Firm Growth	32.22%	55.18%	90.71%
Invested Capital Growth	12.93%	-23.89%	-4.39%
Revenue Q/Q Growth	9.54%	3.42%	4.75%
EBITDA Q/Q Growth	12.68%	9.00%	60.52%
EBIT Q/Q Growth	12.82%	8.86%	57.19%
NOPAT Q/Q Growth	15.97%	8.39%	55.53%
Net Income Q/Q Growth	16.04%	7.64%	51.44%
EPS Q/Q Growth	20.10%	11.11%	25.00%
Operating Cash Flow Q/Q Growth	5.00%	40.48%	-171.63%
Free Cash Flow Firm Q/Q Growth	3.90%	39.20%	59.40%
Invested Capital Q/Q Growth	39.07%	-13.03%	-10.72%
Profitability Metrics	-	-	-
Gross Margin	49.04%	48.75%	73.21%
EBITDA Margin	-166.09%	-85.45%	-6.78%
Operating Margin	-162.21%	-87.07%	-7.99%
EBIT Margin	-168.28%	-86.63%	-7.69%
Profit (Net Income) Margin	-169.05%	-87.02%	-9.41%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	100.46%	100.46%	122.36%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-166.26%	-112.73%	-13.90%
ROIC Less NNEP Spread (ROIC-NNEP)	-379.95%	-154.72%	-19.89%
Return on Net Nonoperating Assets (RNNOA)	-233.17%	1,196.59%	54.06%
Return on Equity (ROE)	-399.43%	1,083.86%	40.16%
Cash Return on Invested Capital (CROIC)	-178.40%	-85.60%	-9.41%
Operating Return on Assets (OROA)	-65.10%	-46.49%	-4.87%
Return on Assets (ROA)	-65.40%	-46.70%	-5.96%
Return on Common Equity (ROCE)	-399.43%	1,083.86%	40.16%
Return on Equity Simple (ROE_SIMPLE)	-1,341.17%	325.43%	40.36%
Net Operating Profit after Tax (NOPAT)	-122	-77	-8.07
NOPAT Margin	-113.55%	-60.95%	-5.59%
Net Nonoperating Expense Percent (NNEP)	213.69%	41.99%	6.00%
Return On Investment Capital (ROIC_SIMPLE)	-75.07%	-55.39%	-6.95%
Cost of Revenue to Revenue	50.96%	51.25%	26.79%
SG&A Expenses to Revenue	57.80%	51.78%	37.01%
R&D to Revenue	76.81%	30.80%	11.56%
Operating Expenses to Revenue	211.25%	135.82%	81.20%
Earnings before Interest and Taxes (EBIT)	-181	-110	-11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-179	-109	-9.79
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	21.90	0.00	0.00
Price to Tangible Book Value (P/TBV)	21.90	0.00	0.00
Price to Revenue (P/Rev)	2.76	2.01	1.61
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.64	5.87	5.69
Enterprise Value to Revenue (EV/Rev)	3.36	2.74	2.24
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	11.00	-5.11	-4.45
Long-Term Debt to Equity	11.00	-5.11	-4.45
Financial Leverage	0.61	-7.73	-2.72
Leverage Ratio	6.11	-23.21	-6.74
Compound Leverage Factor	6.14	-23.31	-8.25
Debt to Total Capital	91.67%	124.30%	129.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	91.67%	124.30%	129.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	8.33%	-24.30%	-29.00%
Debt to EBITDA	-0.83	-1.60	-15.29
Net Debt to EBITDA	-0.36	-0.86	-9.24
Long-Term Debt to EBITDA	-0.83	-1.60	-15.29
Debt to NOPAT	-1.22	-2.24	-18.55
Net Debt to NOPAT	-0.53	-1.21	-11.20
Long-Term Debt to NOPAT	-1.22	-2.24	-18.55
Altman Z-Score	-10.63	-11.87	-9.94
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.49	2.37	2.29
Quick Ratio	1.66	1.76	1.51
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-131	-59	-5.46
Operating Cash Flow to CapEx	-9,193.49%	-3,837.40%	-1,341.81%
Free Cash Flow to Firm to Interest Expense	-53.03	-15.20	-0.91
Operating Cash Flow to Interest Expense	-59.38	-15.20	-3.73
Operating Cash Flow Less CapEx to Interest Expense	-60.03	-15.59	-4.01
Efficiency Ratios	-	-	-
Asset Turnover	0.39	0.54	0.63
Accounts Receivable Turnover	2.46	2.26	2.08
Inventory Turnover	1.07	1.35	0.81
Fixed Asset Turnover	4.69	6.00	8.24
Accounts Payable Turnover	15.62	20.14	5.17
Days Sales Outstanding (DSO)	148.39	161.16	175.84
Days Inventory Outstanding (DIO)	342.41	271.02	449.88
Days Payable Outstanding (DPO)	23.37	18.12	70.59
Cash Conversion Cycle (CCC)	467.42	414.05	555.12
Capital & Investment Metrics	-	-	-
Invested Capital	78	59	57
Invested Capital Turnover	1.46	1.85	2.48
Increase / (Decrease) in Invested Capital	8.93	-19	-2.61
Enterprise Value (EV)	362	348	323
Market Capitalization	297	255	233
Book Value per Share	$0.11	($0.23)	($0.22)
Tangible Book Value per Share	$0.11	($0.23)	($0.22)
Total Capital	163	140	116
Total Debt	149	174	150
Total Long-Term Debt	149	174	150
Net Debt	64	93	90
Capital Expenditures (CapEx)	1.60	1.53	1.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)	38	29	58
Debt-free Net Working Capital (DFNWC)	123	109	118
Net Working Capital (NWC)	123	109	118
Net Nonoperating Expense (NNE)	60	33	5.51
Net Nonoperating Obligations (NNO)	64	93	90
Total Depreciation and Amortization (D&A)	2.36	1.50	1.31
Debt-free, Cash-free Net Working Capital to Revenue	35.50%	22.57%	40.39%
Debt-free Net Working Capital to Revenue	114.31%	85.87%	81.48%
Net Working Capital to Revenue	114.31%	85.87%	81.48%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.67)	($0.80)	($0.09)
Adjusted Weighted Average Basic Shares Outstanding	108.88M	138.14M	152.45M
Adjusted Diluted Earnings per Share	($1.67)	($0.80)	($0.09)
Adjusted Weighted Average Diluted Shares Outstanding	108.88M	138.14M	152.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	119.26M	150.33M	152.33M
Normalized Net Operating Profit after Tax (NOPAT)	-122	-77	-8.07
Normalized NOPAT Margin	-113.55%	-60.95%	-5.59%
Pre Tax Income Margin	-169.05%	-87.02%	-9.41%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-73.24	-28.45	-1.84
NOPAT to Interest Expense	-49.42	-20.02	-1.34
EBIT Less CapEx to Interest Expense	-73.88	-28.85	-2.12
NOPAT Less CapEx to Interest Expense	-50.06	-20.41	-1.62
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Heron Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.32%	45.38%	26.25%	14.95%	18.36%	14.00%	17.07%	13.42%	4.38%	19.13%
EBITDA Growth	19.71%	61.16%	48.00%	24.58%	40.87%	50.68%	85.94%	78.50%	83.48%	147.08%
EBIT Growth	20.08%	61.35%	48.25%	24.76%	40.48%	49.79%	85.49%	78.22%	82.12%	140.83%
NOPAT Growth	19.00%	61.98%	47.45%	14.33%	40.48%	49.79%	85.49%	84.80%	82.12%	158.33%
Net Income Growth	20.04%	63.64%	48.71%	25.37%	40.33%	46.03%	90.36%	78.04%	80.61%	134.16%
EPS Growth	25.49%	79.25%	57.14%	36.36%	55.26%	90.91%	92.59%	82.86%	82.35%	300.00%
Operating Cash Flow Growth	30.28%	17.07%	43.33%	4.26%	75.24%	106.54%	61.78%	83.05%	136.73%	-579.84%
Free Cash Flow Firm Growth	75.26%	70.49%	47.20%	-64.66%	-45.57%	149.52%	114.62%	106.10%	105.28%	-40.95%
Invested Capital Growth	-13.78%	12.93%	27.30%	51.63%	21.71%	-23.89%	-11.79%	-10.30%	-6.86%	-4.39%
Revenue Q/Q Growth	-3.88%	13.07%	-1.38%	7.25%	-1.03%	8.90%	1.28%	3.91%	-8.92%	24.29%
EBITDA Q/Q Growth	25.64%	51.45%	-63.12%	-28.09%	41.71%	59.50%	53.50%	-95.85%	55.19%	215.38%
EBIT Q/Q Growth	25.69%	51.40%	-62.43%	-28.25%	41.21%	59.00%	53.05%	-92.48%	51.73%	193.61%
NOPAT Q/Q Growth	15.39%	51.40%	-62.43%	-28.25%	41.21%	59.00%	53.05%	-34.33%	30.83%	233.72%
Net Income Q/Q Growth	25.64%	52.59%	-64.92%	-28.35%	40.54%	57.12%	70.53%	-192.25%	47.50%	175.56%
EPS Q/Q Growth	30.91%	71.05%	-145.45%	-29.63%	51.43%	94.12%	-100.00%	-200.00%	50.00%	166.67%
Operating Cash Flow Q/Q Growth	-30.64%	-1.26%	33.66%	-9.10%	66.21%	126.75%	-487.62%	51.62%	173.22%	-449.45%
Free Cash Flow Firm Q/Q Growth	40.00%	-13.90%	-71.90%	-40.17%	46.96%	138.75%	-83.70%	-41.55%	-54.09%	333.54%
Invested Capital Q/Q Growth	10.66%	39.07%	-0.15%	-1.32%	-11.18%	-13.03%	95.68%	0.35%	-7.78%	-10.72%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	44.58%	57.95%	43.09%	36.53%	42.08%	71.12%	75.64%	70.80%	71.17%	74.92%
EBITDA Margin	-155.81%	-66.90%	-110.65%	-132.15%	-77.84%	-28.94%	-13.29%	-25.05%	-12.32%	11.44%
Operating Margin	-157.71%	-67.79%	-111.64%	-133.50%	-79.31%	-29.85%	-13.84%	-17.89%	-13.59%	10.23%
EBIT Margin	-157.71%	-67.79%	-111.64%	-133.50%	-79.31%	-29.85%	-13.84%	-25.64%	-13.59%	10.23%
Profit (Net Income) Margin	-157.80%	-66.17%	-110.65%	-132.42%	-79.56%	-31.33%	-9.11%	-25.64%	-14.78%	8.98%
Tax Burden Percent	100.06%	99.87%	99.11%	99.19%	100.32%	105.51%	65.86%	100.00%	108.75%	74.59%
Interest Burden Percent	100.00%	97.74%	100.00%	100.00%	100.00%	99.45%	100.00%	100.00%	100.00%	117.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-179.15%	-69.48%	-127.94%	-172.86%	-109.68%	-38.65%	-17.46%	-23.43%	-19.87%	25.43%
ROIC Less NNEP Spread (ROIC-NNEP)	-54.18%	-89.57%	-143.15%	-185.99%	-121.33%	-43.18%	-17.25%	-27.66%	-21.60%	24.87%
Return on Net Nonoperating Assets (RNNOA)	7.73%	-54.97%	-1,445.72%	574.74%	2,948.91%	333.93%	73.21%	79.89%	63.62%	-67.58%
Return on Equity (ROE)	-171.43%	-124.45%	-1,573.66%	401.88%	2,839.23%	295.28%	55.75%	56.46%	43.75%	-42.16%
Cash Return on Invested Capital (CROIC)	-225.39%	-178.40%	-169.80%	-192.19%	-155.53%	-85.60%	-66.12%	-33.69%	-20.42%	-9.41%
Operating Return on Assets (OROA)	-49.66%	-26.22%	-51.39%	-70.75%	-38.88%	-16.02%	-8.33%	-16.67%	-8.32%	6.48%
Return on Assets (ROA)	-49.69%	-25.60%	-50.93%	-70.17%	-39.00%	-16.81%	-5.49%	-16.67%	-9.05%	5.69%
Return on Common Equity (ROCE)	-171.43%	-124.45%	-1,573.66%	401.88%	2,839.23%	295.28%	55.75%	56.46%	43.75%	-42.16%
Return on Equity Simple (ROE_SIMPLE)	-965.71%	0.00%	1,320.36%	347.73%	430.81%	0.00%	239.74%	126.85%	69.91%	0.00%
Net Operating Profit after Tax (NOPAT)	-29	-14	-23	-30	-17	-7.15	-3.36	-4.51	-3.12	4.17
NOPAT Margin	-110.39%	-47.45%	-78.15%	-93.45%	-55.51%	-20.90%	-9.69%	-12.52%	-9.51%	10.23%
Net Nonoperating Expense Percent (NNEP)	-124.97%	20.10%	15.21%	13.13%	11.66%	4.53%	-0.21%	4.24%	1.73%	0.56%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.75%	-	-	-	-5.12%	-	-	-	3.60%
Cost of Revenue to Revenue	55.42%	42.05%	56.91%	63.47%	57.92%	28.88%	24.36%	29.20%	28.83%	25.08%
SG&A Expenses to Revenue	36.90%	112.32%	53.47%	61.68%	50.63%	42.18%	43.19%	38.60%	37.71%	29.78%
R&D to Revenue	96.19%	-45.77%	29.84%	41.59%	29.54%	22.79%	13.29%	12.30%	13.61%	7.79%
Operating Expenses to Revenue	202.29%	125.74%	154.73%	170.04%	121.38%	100.98%	89.48%	88.69%	84.76%	64.69%
Earnings before Interest and Taxes (EBIT)	-42	-20	-33	-42	-25	-10	-4.80	-9.24	-4.46	4.17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-41	-20	-33	-42	-24	-9.91	-4.61	-9.02	-4.04	4.67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	19.29	21.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	19.29	21.90	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.41	2.76	1.58	1.18	1.18	2.01	3.15	3.87	2.19	1.61
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.32	4.64	3.46	3.32	3.53	5.87	7.55	9.20	6.38	5.69
Enterprise Value to Revenue (EV/Rev)	4.75	3.36	2.37	2.16	1.96	2.74	3.93	4.65	2.94	2.24
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	6.92	11.00	-13.07	-3.80	-6.24	-5.11	-5.15	-4.59	-4.36	-4.45
Long-Term Debt to Equity	6.92	11.00	-13.07	-3.80	-6.24	-5.11	-5.15	-4.59	-4.36	-4.45
Financial Leverage	-0.14	0.61	10.10	-3.09	-24.30	-7.73	-4.24	-2.89	-2.94	-2.72
Leverage Ratio	4.42	6.11	39.48	-7.30	-93.92	-23.21	-9.71	-5.43	-6.64	-6.74
Compound Leverage Factor	4.42	5.97	39.48	-7.30	-93.92	-23.08	-9.71	-5.43	-6.64	-7.93
Debt to Total Capital	87.38%	91.67%	108.29%	135.68%	119.07%	124.30%	124.08%	127.84%	129.75%	129.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	87.38%	91.67%	108.29%	135.68%	119.07%	124.30%	124.08%	127.84%	129.75%	129.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	12.62%	8.33%	-8.29%	-35.68%	-19.07%	-24.30%	-24.08%	-27.84%	-29.75%	-29.00%
Debt to EBITDA	-0.76	-0.83	-1.04	-1.10	-1.45	-1.60	-2.15	-3.85	-7.04	-15.29
Net Debt to EBITDA	-0.16	-0.36	-0.62	-0.85	-0.81	-0.86	-1.27	-2.36	-4.18	-9.24
Long-Term Debt to EBITDA	-0.76	-0.83	-1.04	-1.10	-1.45	-1.60	-2.15	-3.85	-7.04	-15.29
Debt to NOPAT	-1.07	-1.22	-1.47	-1.55	-2.05	-2.24	-3.02	-5.37	-9.62	-18.55
Net Debt to NOPAT	-0.23	-0.53	-0.88	-1.20	-1.14	-1.21	-1.78	-3.29	-5.71	-11.20
Long-Term Debt to NOPAT	-1.07	-1.22	-1.47	-1.55	-2.05	-2.24	-3.02	-5.37	-9.62	-18.55
Altman Z-Score	-7.67	-8.52	-10.56	-12.31	-10.46	-10.39	-10.13	-9.98	-10.35	-9.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.38	2.49	2.29	1.91	2.43	2.37	2.47	2.38	2.28	2.29
Quick Ratio	1.75	1.66	1.43	1.27	1.77	1.76	1.82	1.76	1.61	1.51
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-23	-40	-56	-30	11	5.83	3.41	1.56	6.78
Operating Cash Flow to CapEx	0.00%	-9,132.36%	-11,116.07%	-9,771.58%	-1,157.50%	1,035.87%	0.00%	-722.76%	782.13%	-1,927.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.31	0.39	0.46	0.53	0.49	0.54	0.60	0.65	0.61	0.63
Accounts Receivable Turnover	2.31	2.46	2.46	2.02	2.32	2.26	2.26	1.81	2.11	2.08
Inventory Turnover	1.13	1.07	1.11	1.21	1.44	1.35	1.20	1.08	0.87	0.81
Fixed Asset Turnover	4.33	4.69	5.02	5.32	5.66	6.00	6.47	7.42	7.61	8.24
Accounts Payable Turnover	8.56	15.62	9.82	8.17	16.14	20.14	23.13	7.72	6.36	5.17
Days Sales Outstanding (DSO)	158.32	148.39	148.38	181.01	157.46	161.16	161.32	201.29	173.35	175.84
Days Inventory Outstanding (DIO)	321.65	342.41	328.07	300.43	253.51	271.02	304.30	339.31	419.06	449.88
Days Payable Outstanding (DPO)	42.66	23.37	37.15	44.69	22.61	18.12	15.78	47.25	57.40	70.59
Cash Conversion Cycle (CCC)	437.31	467.42	439.30	436.74	388.35	414.05	449.84	493.35	535.01	555.12
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	56	78	78	77	68	59	69	69	64	57
Invested Capital Turnover	1.62	1.46	1.64	1.85	1.98	1.85	1.80	1.87	2.09	2.48
Increase / (Decrease) in Invested Capital	-8.97	8.93	17	26	12	-19	-9.19	-7.92	-4.68	-2.61
Enterprise Value (EV)	467	362	269	255	241	348	519	634	405	323
Market Capitalization	433	297	180	139	145	255	416	527	302	233
Book Value per Share	$0.22	$0.11	($0.10)	($0.33)	($0.20)	($0.23)	($0.22)	($0.25)	($0.26)	($0.22)
Tangible Book Value per Share	$0.22	$0.11	($0.10)	($0.33)	($0.20)	($0.23)	($0.22)	($0.25)	($0.26)	($0.22)
Total Capital	178	163	138	110	146	140	140	136	134	116
Total Debt	155	149	149	149	173	174	174	174	174	150
Total Long-Term Debt	155	149	149	149	173	174	174	174	174	150
Net Debt	34	64	89	116	96	93	102	107	104	90
Capital Expenditures (CapEx)	-0.12	0.41	0.22	0.28	0.79	0.24	0.00	0.64	0.43	0.61
Debt-free, Cash-free Net Working Capital (DFCFNWC)	8.18	38	40	45	37	29	39	44	39	58
Debt-free Net Working Capital (DFNWC)	130	123	100	79	114	109	111	111	110	118
Net Working Capital (NWC)	130	123	100	79	114	109	111	111	110	118
Net Nonoperating Expense (NNE)	13	5.62	9.62	12	7.56	3.57	-0.20	4.72	1.73	0.51
Net Nonoperating Obligations (NNO)	34	64	89	116	96	93	102	107	104	90
Total Depreciation and Amortization (D&A)	0.50	0.27	0.30	0.43	0.46	0.31	0.19	0.21	0.42	0.49
Debt-free, Cash-free Net Working Capital to Revenue	8.32%	35.50%	35.35%	38.41%	29.98%	22.57%	29.52%	31.90%	28.14%	40.39%
Debt-free Net Working Capital to Revenue	132.18%	114.31%	88.08%	66.60%	92.99%	85.87%	83.67%	81.29%	79.60%	81.48%
Net Working Capital to Revenue	132.18%	114.31%	88.08%	66.60%	92.99%	85.87%	83.67%	81.29%	79.60%	81.48%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.38)	($0.11)	($0.27)	($0.35)	($0.17)	($0.01)	($0.02)	($0.06)	($0.03)	$0.02
Adjusted Weighted Average Basic Shares Outstanding	111.74M	108.88M	119.25M	119.72M	144.99M	138.14M	151.20M	152.31M	152.83M	152.45M
Adjusted Diluted Earnings per Share	($0.38)	($0.11)	($0.27)	($0.35)	($0.17)	($0.01)	($0.02)	($0.06)	($0.03)	$0.02
Adjusted Weighted Average Diluted Shares Outstanding	111.74M	108.88M	119.25M	119.72M	144.99M	138.14M	151.20M	152.31M	152.83M	152.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	118.89M	119.26M	119.71M	140.76M	150.07M	150.33M	150.65M	151.67M	152.09M	152.33M
Normalized Net Operating Profit after Tax (NOPAT)	-29	-14	-23	-30	-17	-7.15	-3.36	-4.51	-3.12	2.92
Normalized NOPAT Margin	-110.39%	-47.45%	-78.15%	-93.45%	-55.51%	-20.90%	-9.69%	-12.52%	-9.51%	7.16%
Pre Tax Income Margin	-157.71%	-66.25%	-111.64%	-133.50%	-79.31%	-29.69%	-13.84%	-25.64%	-13.59%	12.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Heron Therapeutics' Financials

When does Heron Therapeutics's financial year end?

According to the most recent income statement we have on file, Heron Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Heron Therapeutics' net income changed over the last 2 years?

Heron Therapeutics' net income appears to be on a downward trend, with a most recent value of -$13.58 million in 2024, falling from -$182.02 million in 2022. The previous period was -$110.56 million in 2023. Check out Heron Therapeutics' forecast to explore projected trends and price targets.

What is Heron Therapeutics's operating income?

Heron Therapeutics's total operating income in 2024 was -$11.53 million, based on the following breakdown:

Total Gross Profit: $105.64 million
Total Operating Expenses: $117.17 million

How has Heron Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Heron Therapeutics' total revenue changed from $107.67 million in 2022 to $144.29 million in 2024, a change of 34.0%.

How much debt does Heron Therapeutics have?

Heron Therapeutics' total liabilities were at $266.80 million at the end of 2024, a 4.0% increase from 2023, and a 12.4% increase since 2022.

How much cash does Heron Therapeutics have?

In the past 2 years, Heron Therapeutics' cash and equivalents has ranged from $15.36 million in 2022 to $28.68 million in 2023, and is currently $25.80 million as of their latest financial filing in 2024.

How has Heron Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Heron Therapeutics' book value per share changed from 0.11 in 2022 to -0.22 in 2024, a change of -293.8%.

Related Companies

This page (NASDAQ:HRTX) was last updated on 6/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Financials

Frequently Asked Questions About Heron Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Financials

Annual Income Statements for Heron Therapeutics

Quarterly Income Statements for Heron Therapeutics

Annual Cash Flow Statements for Heron Therapeutics

Quarterly Cash Flow Statements for Heron Therapeutics

Annual Balance Sheets for Heron Therapeutics

Quarterly Balance Sheets for Heron Therapeutics

Annual Metrics And Ratios for Heron Therapeutics

Quarterly Metrics And Ratios for Heron Therapeutics

Frequently Asked Questions About Heron Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools